Your browser is no longer supported. Please, upgrade your browser.
Settings
BIOC Biocept, Inc. daily Stock Chart
BIOC [NASD]
Biocept, Inc.
Index- P/E- EPS (ttm)-2.67 Insider Own0.23% Shs Outstand102.84M Perf Week0.04%
Market Cap29.00M Forward P/E- EPS next Y-0.21 Insider Trans0.00% Shs Float102.84M Perf Month-44.47%
Income-25.50M PEG- EPS next Q- Inst Own9.60% Short Float2.16% Perf Quarter-15.77%
Sales4.60M P/S6.30 EPS this Y86.40% Inst Trans296.71% Short Ratio0.16 Perf Half Y-64.39%
Book/sh0.38 P/B0.74 EPS next Y44.30% ROA-136.40% Target Price4.42 Perf Year-73.64%
Cash/sh0.09 P/C3.12 EPS next 5Y40.00% ROE-219.60% 52W Range0.21 - 2.11 Perf YTD-1.40%
Dividend- P/FCF- EPS past 5Y67.90% ROI-193.80% 52W High-86.64% Beta0.05
Dividend %- Quick Ratio2.40 Sales past 5Y110.60% Gross Margin- 52W Low33.52% ATR0.08
Employees88 Current Ratio2.50 Sales Q/Q100.00% Oper. Margin- RSI (14)46.16 Volatility11.24% 20.12%
OptionableNo Debt/Eq0.06 EPS Q/Q86.20% Profit Margin- Rel Volume0.42 Prev Close0.27
ShortableYes LT Debt/Eq0.00 EarningsMar 25 AMC Payout- Avg Volume13.84M Price0.28
Recom2.00 SMA20-8.88% SMA50-16.63% SMA200-56.21% Volume5,831,651 Change5.62%
Nov-14-17Reiterated Chardan Capital Markets Buy $2.50 → $1.50
Jun-02-17Initiated Chardan Capital Markets Buy $2.50
Jun-06-16Initiated ROTH Capital Buy $1.20
Aug-19-15Initiated H.C. Wainwright Buy $4
Jun-03-14Initiated Aegis Capital Buy $16
Apr-02-20 08:05AM  Australia Patent Issued for Primer-Switch Mutation Detection and Amplification Platform PR Newswire
Apr-01-20 07:53PM  For Penny Investors, Biocept Stock Makes a Good Speculative Play SmarterAnalyst
Mar-28-20 08:23AM  US$1.00: That's What Analysts Think Biocept, Inc. (NASDAQ:BIOC) Is Worth After Its Latest Results Simply Wall St.
Mar-26-20 08:05AM  Biocept Enters into Laboratory Services Agreement with Second California-Based Independent Physician Association PR Newswire -12.49%
Mar-25-20 04:05PM  Biocept Reports 2019 Fourth Quarter and Full Year Financial Results PR Newswire +12.43%
02:30PM  Biocept, Inc. to Host Earnings Call ACCESSWIRE
Mar-18-20 08:30AM  Biocept, Inc. Discusses Highlights for 2019, Recent News and What to Look Out For in Q2 2020 in New SNNLive Video Interview on SNN Network ACCESSWIRE -15.04%
08:05AM  Biocept to Release 2019 Fourth Quarter and Full Year Financial Results and Host Investor Conference Call on March 25, 2020 PR Newswire
Mar-11-20 09:23AM  Biotech Maven Hal Mintz Snaps Up These 3 Small Biotech Stocks TipRanks +6.20%
Mar-09-20 08:05AM  Newly Published Data in Journal of Clinical Pathology Provides Clinical Validation for Biocept's Target Selector qPCR Assay to Identify Cancer-Associated Mutations PR Newswire -8.71%
Mar-05-20 08:30AM  Biocept Announces Pricing of $6.6 Million Registered Direct Offering Priced At-The-Market PR Newswire -10.12%
Mar-02-20 10:48AM  Biocept's stock plummets on heavy volume after share offering prices at deep discount MarketWatch -42.31%
08:30AM  Biocept Announces Pricing of $9.2 Million Registered Direct Offering Priced At-The-Market PR Newswire
Feb-14-20 08:05AM  Biocept Appoints Cory J. Dunn Senior Vice President of Commercial Operations PR Newswire
Feb-10-20 08:05AM  Biocept Enters into Laboratory Services Agreement with California-Based Independent Physician Association PR Newswire
Feb-04-20 08:05AM  Biocept to Present at the 22nd Annual BIO CEO & Investor Conference PR Newswire +8.76%
Jan-14-20 08:05AM  Biocept Announces Validation and Availability of its Liquid Biopsy Platform for the Detection of Actionable Cancer Biomarkers in Cerebrospinal Fluid PR Newswire +14.09%
Jan-12-20 08:22AM  How Does Investing In Biocept, Inc. (NASDAQ:BIOC) Impact The Volatility Of Your Portfolio? Simply Wall St.
Jan-08-20 09:00AM  Biocept, Inc. Awarded United States Patent for the Use of Antibodies in Combination with Any Solid Surface to Detect Any Target Cell of Interest - from Any Sample Type PR Newswire
Dec-12-19 08:00AM  Biocept Announces Closing of $10.0 Million Underwritten Public Offering PR Newswire
Dec-10-19 07:56AM  The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares Benzinga
Dec-09-19 09:15AM  Biocept Announces Pricing of $10.0 Million Underwritten Public Offering PR Newswire -49.99%
Dec-03-19 08:05AM  Biocept's Liquid Biopsy CTC Testing for Breast Cancer to Be Featured in Poster Presentation at the 2019 San Antonio Breast Cancer Symposium® PR Newswire
Nov-21-19 08:05AM  Biocept Announces the Launch of its Liquid Biopsy Test to Detect TRK Biomarkers in the Blood of Patients Diagnosed with Cancer PR Newswire +6.48%
Nov-13-19 04:05PM  Biocept Reports Third Quarter 2019 Financial Results PR Newswire
Nov-07-19 08:05AM  Biocept Announces CE IVD Marks and Availability of its CEE-Sure® Blood Collection Tube and Sample Collection Shipping Kit in Europe PR Newswire
Nov-06-19 08:05AM  Biocept to Release Third Quarter 2019 Financial Results and Host Investor Conference Call on November 13, 2019 PR Newswire -5.13%
Nov-04-19 08:05AM  Biocept's Target Selector Tests and Kits to Be Featured in Six Poster Presentations at the 2019 Association for Molecular Pathology Annual Meeting PR Newswire
Oct-14-19 10:05AM  Why Biocept, Inc.'s (NASDAQ:BIOC) CEO Pay Matters To You Simply Wall St.
Oct-07-19 08:05AM  Biocept's Target Selector ctDNA Platform Demonstrates Single Copy Detection for EGFR, BRAF, and KRAS Mutations; Study Results Published in Peer-Reviewed Journal, PLOS ONE PR Newswire
Oct-03-19 08:05AM  Biocept Announces Issuance of South Korean Patent Covering its Target Selector Oncogene Mutation Enrichment and Detection Platform PR Newswire
Sep-03-19 08:05AM  Biocept to Present at Two Investment Conferences in September PR Newswire
Aug-22-19 08:05AM  High Sensitivity of Biocept's Target Selector Platform Using CEE-Sure Blood Collection Tubes to Be Featured in Poster Presentation at the 2019 IASLC World Conference on Lung Cancer PR Newswire
Aug-13-19 08:05AM  Biocept Receives Three Additional Patents Covering its Antibody and Microchannel Technology and Enhanced Detection of Cancer Cells PR Newswire
Aug-12-19 04:05PM  Biocept Reports Second Quarter 2019 Financial Results PR Newswire +6.86%
02:30PM  Biocept, Inc. to Host Earnings Call ACCESSWIRE
Aug-05-19 08:05AM  Biocept to Release Second Quarter 2019 Financial Results and Host Investor Conference Call on August 12, 2019 PR Newswire
Aug-04-19 10:02PM  Penny Stocks to Watch for August 2019 Investopedia
Jul-22-19 08:05AM  Biocept Announces Laboratory Services Provider Agreement with BeaconLBS® PR Newswire
Jul-16-19 01:31PM  Does Biocept, Inc. (NASDAQ:BIOC) Have A High Beta? Simply Wall St.
Jun-18-19 08:05AM  Biocept Announces Commercial Launch of Target Selector NGS Breast Panel, the Company's Second Multi-Gene Tumor-Specific Panel PR Newswire +10.78%
Jun-03-19 08:05AM  Biocept to Present at the 9th Annual LD Micro Invitational Conference on June 4 PR Newswire
May-28-19 08:05AM  Biocept Awarded Patent in China for its Circulating Tumor Cell Platform Expanding Intellectual Property Estate to 33 Issued Patents Globally PR Newswire +11.29%
May-20-19 03:07PM  Biocept's stock soars on heavy volume after commercial launch of liquid biopsy test for lung cancer MarketWatch +95.12%
08:05AM  Biocept Announces Clinical Validation and Commercial Launch of its Target Selector Multi-Gene Liquid Biopsy Panel for Lung Cancer PR Newswire
May-08-19 04:05PM  Biocept Reports First Quarter 2019 Financial Results PR Newswire
May-01-19 08:05AM  Biocept to Release First Quarter 2019 Financial Results and Host Investor Conference Call on May 8, 2019 PR Newswire
Mar-28-19 04:05PM  Biocept Reports 2018 Fourth Quarter and Full Year Financial Results PR Newswire
Mar-26-19 08:05AM  Biocept Broadens Commercial Focus of its Target Selector Liquid Biopsy Platform to Include Urology Market Segment PR Newswire +19.42%
Mar-21-19 08:05AM  Biocept to Release 2018 Fourth Quarter and Full Year Financial Results and Host Investor Conference Call on March 28, 2019 PR Newswire
Mar-18-19 08:05AM  Biocept Awarded Patent in Japan for the Capture of Rare Cells Including CTCs from Any Biological Sample of Interest with A Microchannel Device PR Newswire -7.69%
08:00AM  Biocept, Potential Near-Term Catalysts for Biocept ACCESSWIRE
Mar-15-19 09:00AM  Biocept Announces Pricing of $8.2 Million Registered Direct Offering PR Newswire -25.95%
Mar-13-19 08:05AM  Biocept Expands its Pathology Partnership Offering for Liquid Biopsy with the Addition of Several Key Services PR Newswire
Mar-04-19 08:05AM  Biocept's Liquid Biopsy Test for ESR1 Biomarker Detection to be Featured in Poster Presentation at the 2019 AACR Annual Meeting PR Newswire
Feb-27-19 10:00AM  Four Healthcare Stocks Getting A Boost On Wednesday ACCESSWIRE
08:05AM  Biocept and Providence Saint John's Health Center Collaborate to Evaluate Cerebrospinal Fluid for Use with Liquid Biopsy Testing in Metastatic Cancer PR Newswire
Feb-20-19 08:05AM  Biocept Issues Letter to Stockholders PR Newswire
Feb-13-19 09:34AM  What Makes Biocept (BIOC) a New Buy Stock Zacks
Feb-08-19 08:45AM  Biocept Announces Pricing of $7.5 Million Underwritten Public Offering PR Newswire -47.29%
Feb-07-19 08:42AM  Biocept Announces Agreement with Agiomix FZ-LLC for Target Selector Liquid Biopsy Kits PR Newswire +7.98%
Feb-05-19 08:05AM  Published Case Series Indicates the Ability of Biocept's Liquid Biopsy Testing to Identify Actionable Biomarkers When Tissue Biopsy Is Unsuccessful PR Newswire
Jan-30-19 08:20AM  Biocept, Inc., Pipeline Review, Upcoming Catalysts and Milestones ACCESSWIRE
Jan-28-19 08:05AM  Biocept Launches Liquid Biopsy Kits Intended to Broaden Use of its Proprietary Technology Platform for High Sensitivity Detection of Circulating Tumor DNA PR Newswire +8.76%
Jan-22-19 02:45PM  Should You Worry About Biocept, Inc.s (NASDAQ:BIOC) CEO Salary Level? Simply Wall St. -14.85%
Jan-18-19 09:00AM  Biocept Announces Pricing of $2.2 Million Registered Direct Offering PR Newswire -24.42%
Jan-17-19 07:55AM  Today's Research Reports on Trending Tickers: Adamis Pharmaceuticals and Biocept ACCESSWIRE +29.49%
Dec-19-18 06:55AM  Today's Research Reports on Trending Tickers: Biogen and Biocept ACCESSWIRE -29.82%
Dec-18-18 08:05AM  Biocept and Prognos Enter Into Partnership to Apply Artificial Intelligence in Order to Help Pharmaceutical and Life Sciences Companies Optimize Commercialization of Biomarker-Targeted Therapies in Oncology PR Newswire +66.28%
Nov-29-18 08:09AM  The Daily Biotech Pulse: Twist In Protagonist Tale, Catalyst's Autoimmune Disorder Drug Approved Benzinga
Nov-20-18 01:19PM  What Kind Of Shareholder Appears On The Biocept Incs (NASDAQ:BIOC) Shareholder Register? Simply Wall St.
Nov-13-18 04:05PM  Biocept Reports Third Quarter 2018 Financial Results PR Newswire
Nov-06-18 08:05AM  Biocept to Release Third Quarter 2018 Financial Results and Host Investor Conference Call on November 13, 2018 PR Newswire -6.73%
Nov-05-18 08:05AM  Biocept Announces New Executive Hires to its Sales and Marketing Organization PR Newswire +5.05%
Nov-01-18 11:28AM  Biocept (BIOC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks +5.79%
Oct-23-18 08:05AM  Biocept to Present at the Dawson James Securities Small Cap Growth Conference on October 30 PR Newswire
Oct-18-18 08:05AM  Biocept Obtains Japanese Patent for its Target Selector Oncogene Mutation Enrichment and Detection Platform PR Newswire
Sep-25-18 08:05AM  Biocept to Present at The MicroCap Conference in New York on October 2 PR Newswire
Sep-24-18 08:05AM  Biocept Awarded Patent in Hong Kong for its Target Selector Platform Using Antibodies and a Microchannel to Perform Liquid Biopsy PR Newswire
Sep-21-18 07:00AM  Biocept Announces Pricing of $2.5 Million Registered Direct Offering Priced at Market PR Newswire -11.98%
Sep-10-18 08:05AM  Biocept Names Edwin C. Hendrick as Senior Vice President, Chief Commercial Officer PR Newswire
Sep-06-18 08:05AM  Biocept's Target Selector Platform Featured in Two Poster Presentations at the IASLC 19th World Conference on Lung Cancer PR Newswire
Aug-23-18 10:30AM  Highmark Health's VITAL Innovation Program testing benefits of Biocept's liquid biopsy platform for improving outcomes and lowering costs of treatment for patients with non-small cell lung cancer PR Newswire +18.33%
Aug-15-18 08:48AM  The Daily Biotech Pulse: Vertex Awaits FDA Verdict, Strongbridge Falls On Offering, ReShape's Woes Continue Benzinga -12.88%
Aug-14-18 04:05PM  Biocept Reports Second Quarter 2018 Financial Results PR Newswire -6.17%
Aug-09-18 04:05PM  Biocept to Release Second Quarter 2018 Financial Results and Host Investor Conference Call on August 14, 2018 PR Newswire
08:05AM  Biocept Announces $11.6 Million in Expected Gross Proceeds from Recently Expired Rights Offering PR Newswire
Aug-06-18 08:05AM  Biocept Announces Agreement with Managed Care Plan to Study the Benefits of Implementing Liquid Biopsy to Improve Patient Outcomes and Lower Healthcare Costs PR Newswire
Aug-02-18 08:05AM  Biocept Awarded Patent in Canada for its Target Selector CTC Platform PR Newswire
Jul-31-18 08:05AM  European Patent Granted for Biocept's Target Selector Oncogene Mutation Enrichment and Detection Platform PR Newswire
Jul-23-18 08:05AM  Biocept and UC San Diego Moores Cancer Center Announce Collaboration to Study Feasibility of Liquid Biopsy to Predict Disease Recurrence in Solid Tumors and Response to Therapy PR Newswire
Jul-19-18 09:00AM  Biocept Reminds Investors of Today's Deadline to be a Shareholder of Record PR Newswire
Jul-16-18 08:39AM  Biocept, Inc. (BIOC) Soars: Stock Adds 9.8% in Session Zacks
08:10AM  Today's Research Reports on Stocks to Watch: Biocept and Johnson and Johnson ACCESSWIRE
Jul-13-18 04:49PM  Why RH, Biocept, and Lowe's Jumped Today Motley Fool +9.77%
03:46PM  BIOC: Whats Going on With Biocept Stock? InvestorPlace
01:02PM  Why Biocept, Inc. Is Rebounding Big-Time Today Motley Fool
11:00AM  Biocept Rallies On Marketing Agreement For Proprietary Liquid Biopsy Tests Benzinga
08:05AM  Biocept Enters into Agreement with Alliance Global FZ to Market and Distribute Liquid Biopsy Testing in the Middle East, Southeast Asia, and Africa Region PR Newswire
Jul-12-18 12:26PM  Why Biocept, Inc. Stock Is Plunging Today Motley Fool -17.30%
Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. It offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreatic biliary cancer, and ovarian cancer. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.